Olanzapine induced neuroleptic malignant syndrome.

Abstract

An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.

• Authors: Bichitra Nanda Patra, Sudhir K Khandelwal, Mamta Sood
• Journal: Indian journal of pharmacology (Indian J Pharmacol) 2013 Jan-Feb Vol. 45 Issue 1 Pg. 98-9 ISSN: 1998-3751 [Electronic] India
• PMID: 23543750 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Benzodiazepines
• Olanzapine

Topics

• Adolescent
• Antipsychotic Agents (adverse effects)
• Benzodiazepines (adverse effects)
• Bipolar Disorder (drug therapy)
• Humans
• Male
• Neuroleptic Malignant Syndrome (etiology)
• Olanzapine
• Severity of Illness Index